Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;54(11):2923-2925.
doi: 10.1161/STROKEAHA.123.043019. Epub 2023 Oct 6.

Advances in Stroke: Brain Health in 2023

Tatjana Rundek  1 , Christopher L H Chen  2
Affiliations

Advances in Stroke: Brain Health in 2023

Tatjana Rundek et al. Stroke. 2023 Nov.
No abstract available

Keywords: anticoagulants; edema; iatrogenic disease; inflammation; lecanemab.

PubMed Disclaimer

Conflict of interest statement

Disclosures Dr Chen is a site principal investigator for the CLARITY and AHEAD studies funded by Eisai, the GRADUATE study funded by Roche, and principal investigator for the ATHENE and MAESTOSO studies funded by Moleac. He serves on advisory boards for Actinogen and Eisai. The other authors report no conflicts.

References

    1. Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease. J Prev Alzheimers Dis. 2022;9(2):197–210. - PubMed
    1. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;5;388(1):9–21. - PubMed
    1. Cummings J, Lee G, Nahed P, Kambar MEZN, Zhong K, Fonseca J, Taghva K. Alzheimer’s disease drug development pipeline: 2022. Alzheimers Dement (N Y). 2022;8(1):e12295. - PMC - PubMed
    1. Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023; 330(6):512–527. - PMC - PubMed
    1. Thambisetty M, Howard R Lecanemab trial in AD brings hope but requires greater clarity. Nat Rev Neurol. 2023;19,132–133. - PubMed